New antibiotics for Gram-negative pneumonia

Eur Respir Rev. 2022 Dec 21;31(166):220119. doi: 10.1183/16000617.0119-2022. Print 2022 Dec 31.

Abstract

Pneumonia is frequently encountered in clinical practice, and Gram-negative bacilli constitute a significant proportion of its aetiology, especially when it is acquired in a hospital setting. With the alarming global rise in multidrug resistance in Gram-negative bacilli, antibiotic therapy for treating patients with pneumonia is challenging and must be guided by in vitro susceptibility results. In this review, we provide an overview of antibiotics newly approved for the treatment of pneumonia caused by Gram-negative bacilli. Ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam have potent activity against some of the carbapenem-resistant Enterobacterales, especially Klebsiella pneumoniae carbapenemase producers. Several novel antibiotics have potent activity against multidrug-resistant Pseudomonas aeruginosa, such as ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relabactam and cefiderocol. Cefiderocol may also play an important role in the management of pneumonia caused by Acinetobacter baumannii, along with plazomicin and eravacycline.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents* / adverse effects
  • Carbapenems
  • Cefiderocol
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial
  • Gram-Negative Bacteria
  • Humans
  • Imipenem
  • Pneumonia, Bacterial* / diagnosis
  • Pneumonia, Bacterial* / drug therapy

Substances

  • Anti-Bacterial Agents
  • Imipenem
  • Carbapenems
  • Drug Combinations